SecBot SecBot
SECBOTREPLAY Home › Report › PCVX

PCVX · Vaxcyte entered into an at-the-market (ATM) sales agreement with…

Vaxcyte, Inc. · 8-K filed Feb 24, 2026 at 17:21 ET

At the news

NEUTRALIMPACT 4/10

8-K filed Feb 24, 2026 at 17:21 ET

Vaxcyte entered into an at-the-market (ATM) sales agreement with Leerink Partners LLC to sell up to $500 million in common stock. The company also terminated its prior ATM agreement with Jefferies LLC, under which it had raised approximately $270.3 million. This new facility provides Vaxcyte with ongoing access to capital markets, subject to market conditions and its discretion on timing and size of offerings.

  • Vaxcyte entered into a new sales agreement with Leerink Partners LLC for an at-the-market equity offering program.
  • The maximum aggregate offering amount under the new agreement is $500,000,000.
  • The shares are registered under an existing shelf registration statement (Form S-3) that became effective on May 24, 2024.
  • Leerink Partners will act as sales agent and receive a commission of up to 3.00% of the gross proceeds.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access